Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide. Read more at straitstimes.com. Read ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon ...

Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of ...

A recent study suggests that liraglutide, a drug similar to Ozempic, may reduce migraine frequency in obese individuals with ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their first serious rival in China. Suzhou-based Innovent Biologics Inc. secured ...

Innovent Biologics gains approval for mazdutide, introducing competition to Novo Nordisk and Eli Lilly in China's obesity drug market. Elon Musk criticizes the Senate tax and spending bill, warning it ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Nick Griffin reveals the structural shifts driving Munro’s global growth strategy, from AI and obesity drugs to defence and ...

Early intervention is crucial, as childhood obesity can lead to long-term health issues such as diabetes and heart disease. Dr Thabeng Leping from Novo Nordisk shared alarming statistics regarding the ...